0001894525 2026-03-20 2026-03-20 true --12-31 0001894525 8-K/A 2026-03-20 Apimeds Pharmaceuticals US, Inc. DE 001-42545 85-1099700 100 Matawan Rd Suite 325 Matawan NJ 07747 848 201-5010 true false false false Common Stock, par value $0.01 per share APUS NYSEAMER true false This Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”), originally filed by Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on March 25, 2026 (the “Original Report”), is being filed to clarify that the actions previously reported as having been taken by the majority stockholders of the Company, as described in the Original Report, are null and void and of no force or effect.